Results 201 to 210 of about 74,566 (254)

Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs.

Journal of Medicinal Chemistry, 2020
Tropomyosin receptor kinases (TRKs) are promising cancer therapeutic targets. Chen ( J. Med. Chem. 2020, DOI: 10.1021/acs.jmedchem.0c01342) report the discovery of CG416 and CG428 as two potent small-molecule proteolysis-targeting chimera (PROTAC ...
Weiguo Xiang, Shaomeng Wang
semanticscholar   +4 more sources

Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.

JAMA Oncology, 2023
Importance Thyroid epithelial malignant neoplasms include differentiated thyroid carcinomas (papillary, follicular, and oncocytic), follicular-derived high-grade thyroid carcinomas, and anaplastic and medullary thyroid carcinomas, with additional rarer ...
R. Haddad, R. Elisei, A. O. Hoff, Zhiyan Liu, F. Pitoia, G. Pruneri, P. Sadow, F. Soares, A. Turk, Michelle D Williams, L. Wirth, M. Cabanillas   +11 more
semanticscholar   +4 more sources

Primary sensory neurons expressing tropomyosin receptor kinase A in the rat trigeminal ganglion

Neuroscience Letters, 2019
Tropomyosin receptor kinase A (trkA), a high affinity receptor for nerve growth factor (NGF), has been implicated in neuronal survival, neurite outgrowth and inflammatory pain. So far, the characterization of the primary sensory neurons that express trkA, and are thus potentially affected by NGF, has remained incomplete.
Hyemin Han, Tae Heon Kim, J. Bae, Y. Bae
semanticscholar   +3 more sources

Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis

Expert Review of Anticancer Therapy, 2023
NTRK gene fusions have been identified in various tumors; some requiring aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a national, unselected, retrospective, multicenter cohort.Patients were identified through the French sarcoma diagnostic laboratory at Institut Curie through samples analyzed by RT-qPCR or whole ...
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne Sophie Defachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J Brisse, Gudrun Schleiermacher, Olivier Delattre, Gaëlle Pierron, Daniel Orbach   +21 more
openaire   +2 more sources

Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson’s

Neurological Sciences, 2023
Parkinson's disease is a complex age-related progressive dopaminergic neurodegenerative disease consistently viewed as a disorder of movement and is characterized by its cardinal motor symptoms. While the motor symptoms and its clinical manifestations are attributed to the nigral dopaminergic neuronal death and basal ganglia dysfunction, studies have ...
Jeyaram Bharathi J, Nagarjuna Palathoti, Muralikrishnan Dhanasekaran, R. Sivasamy, Sivasankaran Ponnusankar, S. P. Dhanabal, V. Sankar, Antony Justin   +7 more
openaire   +2 more sources

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers

Future Oncology, 2020
Gene fusions involving NTRK1, NTRK2 and NTRK3 are oncogenic drivers across a wide variety of cancer types. Inhibitors of the chimeric TRKA/B/C protein kinases encoded by these fusions are now available, including larotrectinib, a potent and highly selective oral drug.
Anna F Farago, George D Demetri
openaire   +2 more sources